Article

Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancers

2024-07-14

Abstract excerpt

<h4>ABSTRACT</h4> Breast and ovarian cancers harboring homologous recombination deficiency (HRD) are sensitive to PARP inhibitors and platinum chemotherapy. Conventionally, detecting HRD involves screening for defects in BRCA1 , BRCA2 , and other relevant genes. Recent analyses have shown that HRD cancers exhibit characteristic mutational patterns due to the activities of HRD-associated mutational signatures. A...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bd48f4c4-71de-5dc4-a66a-8c8716d437fd
DOI: 10.1101/2024.07.14.24310383

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancersDOI 10.1101/2024.07.14.24310383Read

HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data.Semantic proximity Read

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.Semantic proximity Read

Leveraging Whole-Exome Sequencing and Mutational Signatures to Detect Homologous Recombination Deficiency in Cancer.Semantic proximity Read

Validation of Genomic and Transcriptomic Models of Homologous Recombination Deficiency in a Real-World Pan-Cancer CohortSemantic proximity Read

HRDex: a tool for deriving homologous recombination deficiency (HRD) scores from whole exome sequencing dataSemantic proximity Read

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer CohortSemantic proximity Read

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohortSemantic proximity Read

Whole Genome Analysis Identifies Homologous Recombination Deficiency in Cancers with BRCA1/2 Wild-Type and BRCA1/2 Structural VariantsSemantic proximity Read

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profilesSemantic proximity Read

Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read